The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
10 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $10,275,834 in first-year total cost, median $999,488.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-F (O1)]5
- Special Emphasis Panel[ZHL1 CSR-F (O2)]5
Most frequent institutions
- ALLEVIANT MEDICAL, INC.1
- AQUALUNG THERAPEUTICS CORP.1
- CROSSLINER INC1
- GLYCAN THERAPEUTICS CORPORATION1
- HEMEX HEALTH, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease2R44HL102998-04 | SEWARD, KIRK | MERCATOR MEDSYSTEMS, INC., CA | $1,000,000 | ZHL1 |
| 2024 | Transcatheter Device for Congestive Heart Failure Treatment Through Left Atrial Decompression2R44HL142440-04 | PATE, THOMAS DIFFLEY | ALLEVIANT MEDICAL, INC., TX | $997,944 | ZHL1 |
| 2024 | Catheter for Complex Percutaneous Coronary Intervention2R44HL152835-04 | FISCHELL, TIM ALEXANDERMIRIZZI, MICHAELSALTIEL, FRANK S | CROSSLINER INC, MI | $994,964 | ZHL1 |
| 2024 | Translation of a personalized, non-invasive smartphone app for hemoglobin monitoring for chronic anemia patients2R44HL139250-04 | TYBURSKI, ERIKA AMY | SANGUINA, LLC, GA | $986,670 | ZHL1 |
| 2024 | Development of dekaparin to replace animal-sourced heparin2R44HL139187-04 | PAGADALA, VIJAYAKANTH | GLYCAN THERAPEUTICS CORPORATION, NC | $747,280 | ZHL1 |
| 2023 | A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial2R44HL145930-04 | GARCIA, JOE G. N. | AQUALUNG THERAPEUTICS CORP., FL | $1,500,000 | ZHL1 |
| 2023 | ErythroMer: Nanoscale BioSynthetic Red Cell Substitute2R44HL135965-04A1 | ALP, ESMABUEHLER, PAUL WERNER | KALOCYTE, INC., MD | $1,050,000 | ZHL1 |
| 2023 | Non-Invasive Venous Waveform Analysis (NIVA) in patients with Heart Failure (HF)2R44HL140669-04A1 | HOCKING, KYLE MITCHELLLINDENFELD, JOANN | VOLUMETRIX, LLC, TN | $1,000,000 | ZHL1 |
| 2023 | Affordable, quantitative, point-of-care microchip-electrophoresis for screening and treatment monitoring of sickle cell disease, thalassemias, and anemias2R44HL140739-04 | GALEN, PETER | HEMEX HEALTH, INC., OR | $1,000,000 | ZHL1 |
| 2023 | New generation of catheters for treatment of atrial fibrillation2R44HL120511-04A1 | AMIRANA, OMARRANSBURY, TERRYSARVAZYAN, NARINE | LUXMED SYSTEMS, INC., MA | $998,976 | ZHL1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-11-0.1.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.